89bio, Inc. - Common Stock (OQ:ETNB)

Apr 17, 2024 04:05 pm ET
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin...
Apr 05, 2024 04:05 pm ET
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
Mar 27, 2024 08:00 am ET
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the European Medicines...
Mar 12, 2024 08:00 am ET
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of its Phase 3...
Mar 08, 2024 04:05 pm ET
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
Mar 05, 2024 04:05 pm ET
89bio to Participate in the Leerink Partners Global Biopharma Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management...
Feb 29, 2024 04:05 pm ET
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the...
Feb 06, 2024 04:05 pm ET
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management...
Feb 05, 2024 04:05 pm ET
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
Dec 19, 2023 04:05 pm ET
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
Dec 12, 2023 07:30 am ET
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it closed its...
Dec 07, 2023 07:00 am ET
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its...
Dec 06, 2023 04:36 pm ET
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced...
Dec 04, 2023 07:00 am ET
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced a successful end-of-Phase 2...
Nov 27, 2023 08:00 am ET
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced positive topline data from the...
Nov 21, 2023 04:01 pm ET
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management...
Nov 12, 2023 12:15 pm ET
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced additional data from a post-hoc...
Nov 08, 2023 04:01 pm ET
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the...
Oct 17, 2023 08:00 am ET
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Management...
Oct 12, 2023 09:31 am ET
Thinking about buying stock in Sellas Life Sciences Group, Silk Road Medical, Hyliion Holdings, 89bio, or OpGen?
NEW YORK, Oct. 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SLS, SILK, HYLN, ETNB, and OPGN.
Oct 11, 2023 09:31 am ET
Thinking about buying stock in Profrac Holding, Camber Energy, Acurx Pharmaceuticals, 89bio, or SuperCom Ltd.?
NEW YORK, Oct. 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACDC, CEI, ACXP, ETNB, and SPCB.
Oct 03, 2023 04:05 pm ET
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
Sep 21, 2023 08:00 am ET
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the U.S. Food and Drug...
Sep 20, 2023 08:00 am ET
89bio to Participate in the 2023 Cantor Global Healthcare Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Management...
Sep 05, 2023 08:00 am ET
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management...
Aug 09, 2023 04:01 pm ET
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the...
Jul 12, 2023 04:30 pm ET
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
Jul 12, 2023 09:31 am ET
Thinking about buying stock in Lucid Group, Aurora Innovation, Enphase Energy, 89bio, or Ardelyx?
NEW YORK, July 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, AUR, ENPH, ETNB, and ARDX.
Jun 24, 2023 05:05 am ET
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the previously reported...
Jun 24, 2023 05:01 am ET
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-br
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that data from the Phase 2b...
Jun 07, 2023 04:05 pm ET
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that...
Jun 07, 2023 08:00 am ET
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that pegozafermin data in...
May 31, 2023 11:20 am ET
Thinking about buying stock in Krystal Biotech, Axsome Therapeutics, 89bio, Scpharmaceuticals, or Decibel Therapeutics?
NEW YORK, May 31, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KRYS, AXSM, ETNB, SCPH, and DBTX.
May 23, 2023 08:00 am ET
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of ENTRUST, a...
May 04, 2023 04:05 pm ET
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
May 02, 2023 08:00 am ET
89bio to Participate in Upcoming Investor Conferences
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Management...
Mar 24, 2023 07:00 am ET
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its...
Mar 22, 2023 04:16 pm ET
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has...
Mar 22, 2023 08:44 am ET
Thinking about buying stock in GameStop, 89bio, Cidara Therapeutics, AMC Entertainment, or So-Young?
NEW YORK, March 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, ETNB, CDTX, AMC, and SY.
Mar 22, 2023 07:00 am ET
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2
30mg QW dose had a placebo-adjusted effect size of 19% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 21% on NASH resolution without worsening of fibrosis (p=0.0009) - - 44mg Q2W and 30mg QW doses had at...
Mar 10, 2023 08:00 am ET
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Mar 04, 2023 01:30 pm ET
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Togeth
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the presentation of additional...
Feb 21, 2023 08:00 am ET
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of C
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data...
Feb 08, 2023 08:00 am ET
89bio to Participate in the SVB Securities Global Biopharma Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that the Company’s Management...
Jan 04, 2023 04:01 pm ET
89bio Provides Business Update and Outlook for 2023
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today provided a corporate update, including...
Dec 12, 2022 06:30 pm ET
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that data from cohorts 1-6 in...
Nov 10, 2022 04:05 pm ET
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Nov 05, 2022 01:00 pm ET
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the presentation of post-hoc...
Oct 21, 2022 09:32 am ET
Thinking about buying stock in Purecycle Technologies, Sellas Life Sciences, Nurix Therapeutics, Pineapple Energy, or 89bio?
NEW YORK, Oct. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PCT, SLS, NRIX, PEGY, and ETNB.
Oct 18, 2022 08:30 am ET
Thinking about buying stock in RA Medical, Aveo Pharmaceuticals, FuboTV, Canoo, or 89bio?
NEW YORK, Oct. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RMED, AVEO, FUBO, GOEV, and ETNB.
Oct 13, 2022 08:00 am ET
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Sep 14, 2022 09:31 am ET
Thinking about buying stock in Caladrius Biosciences, Timber Pharmaceuticals, 89Bio, Alaunos Therapeutics, or SoFi Technologies?
NEW YORK, Sept. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLBS, TMBR, ETNB, TCRT, and SOFI.
Sep 13, 2022 08:30 am ET
Thinking about buying stock in Akero Therapeutics, Planet Labs, Kaspien Holdings, Neurobo Pharmaceuticals, or 89Bio?
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKRO, PL, KSPN, NRBO, and ETNB.
Sep 07, 2022 08:00 am ET
89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that Company’s Management will...
Aug 26, 2022 06:00 am ET
89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the presentation of data from...
Aug 18, 2022 08:00 am ET
89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has completed...
Aug 17, 2022 09:33 am ET
Thinking about buying stock in Cogent Biosciences, FuboTV, 89bio, Kirkland's, or Party City?
NEW YORK, Aug. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COGT, FUBO, ETNB, KIRK, and PRTY.
Aug 11, 2022 08:00 am ET
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Jul 05, 2022 08:00 am ET
89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the closing of its...
Jun 29, 2022 01:47 am ET
89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its...
Jun 28, 2022 04:02 pm ET
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants
89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced...
Jun 28, 2022 04:01 pm ET
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
89bio, Inc. (Nasdaq: ETNB), today announced positive topline results from ENTRIGUE, the Phase 2 proof-of-concept study evaluating pegozafermin for the treatment of severe hypertriglyceridemia (SHTG). Treatment with pegozafermin resulted in...
Jun 21, 2022 08:00 am ET
89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data...
May 11, 2022 04:05 pm ET
89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
May 03, 2022 08:00 am ET
89bio to Participate in Upcoming Investor Conferences
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Apr 26, 2022 08:00 am ET
89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it will host a key...
Mar 24, 2022 04:05 pm ET
89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Mar 01, 2022 04:03 pm ET
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended...
Feb 24, 2022 08:00 am ET
89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of E. Morrey...
Feb 09, 2022 08:00 am ET
89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Jan 24, 2022 04:05 pm ET
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced positive topline results from...
Nov 14, 2021 06:30 pm ET
89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume 
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the presentation of new data...
Nov 11, 2021 04:05 pm ET
89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Nov 03, 2021 08:00 am ET
89bio Announces Appointment of Kathy LaPorte to its Board of Directors
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy...
Oct 25, 2021 04:05 pm ET
89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that a sub-analysis of its...
Sep 21, 2021 08:00 am ET
89bio to Participate in the Cantor Global Healthcare Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Sep 08, 2021 04:15 pm ET
89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Aug 12, 2021 04:05 pm ET
89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Aug 03, 2021 04:15 pm ET
89bio to Participate in Upcoming Investor Conferences
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Aug 02, 2021 08:30 am ET
89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has completed target...
Jun 16, 2021 08:00 am ET
89bio to Participate in Upcoming Investor Conferences
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Jun 10, 2021 08:30 am ET
89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the initiation of ENLIVEN, a...
May 12, 2021 04:05 pm ET
89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
May 05, 2021 08:00 am ET
89bio to Present at Upcoming Investor Conferences
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Apr 05, 2021 08:00 am ET
89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced it has received written...
Mar 24, 2021 04:05 pm ET
89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Mar 20, 2021 11:00 am ET
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional positive data from...
Mar 11, 2021 08:00 am ET
89bio to Present at the Oppenheimer 31st Annual Healthcare Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Mar 03, 2021 08:00 am ET
89bio to Participate in the H.C. Wainwright Global Life Sciences Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Feb 24, 2021 08:00 am ET
89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Feb 18, 2021 08:00 am ET
89bio to Present at the SVB Leerink 10ᵗʰ Annual Global Healthcare Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will...
Jan 05, 2021 08:00 am ET
89bio Provides Business Outlook for 2021
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today provided a corporate update, including...
Jan 04, 2021 08:00 am ET
89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Nov 24, 2020 08:00 am ET
89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Nov 13, 2020 08:00 am ET
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD’s The Liver Meeting® 2020
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced updated data from its positive...
Nov 10, 2020 04:02 pm ET
89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Nov 02, 2020 08:00 am ET
89bio To Present Data From Phase 1b/2a Study of BIO89-100 In NASH at AASLD’s The Liver Meeting® 2020
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that clinical data from its...
Sep 28, 2020 05:18 pm ET
89bio to Present at Upcoming Investor Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Sep 23, 2020 07:00 am ET
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date,...
Sep 16, 2020 08:51 pm ET
89bio Announces Pricing of Upsized Public Offering of Common Stock
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized...
Sep 14, 2020 05:21 pm ET
89bio Announces Proposed Public Offering of Common Stock
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an...
Sep 14, 2020 07:01 am ET
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
89bio, Inc. (Nasdaq: ETNB) today announced positive topline results from its Phase 1b/2a trial with BIO89-100, an investigational FGF21 analog, in patients with nonalcoholic steatohepatitis (NASH). All dose groups demonstrated significant...
Sep 13, 2020 07:53 pm ET
89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH
89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study of BIO89-100 in NASH in a pre-market press release and webcast to be held on Monday, September 14,...
Sep 03, 2020 08:30 am ET
89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the initiation of a Phase 2...
Aug 13, 2020 04:05 pm ET
89bio Reports Second Quarter 2020 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Aug 03, 2020 04:05 pm ET
89bio to Present at Upcoming Investor Conferences
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Jul 13, 2020 10:18 am ET
89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced the closing of its upsized...
Jul 07, 2020 09:30 pm ET
89bio Announces Pricing of Upsized Public Offering of Common Stock
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized...
Jul 06, 2020 06:30 am ET
89bio Announces Proposed Public Offering of Common Stock
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an...
Jun 04, 2020 08:00 am ET
89bio Appoints Veteran Finance Executive Lota Zoth to Board of Directors
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Lota S....
May 13, 2020 04:05 pm ET
89bio Reports First Quarter 2020 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
May 08, 2020 07:30 am ET
89bio to Present at Upcoming Investor Conferences
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Apr 13, 2020 08:30 am ET
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism
SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic...
Mar 25, 2020 04:05 pm ET
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Steven...
Mar 18, 2020 04:05 pm ET
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Feb 21, 2020 04:05 pm ET
89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the...
Dec 18, 2019 04:05 pm ET
89bio Reports Third Quarter 2019 Financial Results and Provides Corporate Update
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the...
Nov 13, 2019 04:02 pm ET
89bio Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the closing of its upsized...
Nov 11, 2019 09:25 am ET
89bio Announces Presentations of BIO89-100 Data at The Liver Meeting® 2019
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that two posters related to its investigational therapy, BIO89-100, will be presented today at The Liver Meeting 2019, the annual meeting of the American Association...
Nov 11, 2019 08:22 am ET
89bio Announces Pricing of Upsized Initial Public Offering
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its upsized...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.